Ad A. van Bodegraven

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

Geert D’Haens, Filip Baert, Gert Van Assche et al. · The Lancet · 2008 · 1.2K citations

Autoimmune Disease, Immunosuppressive Therapy, Immunology +5

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

Mirthe E. van der Valk, Marie‐Josée J. Mangen, Max Leenders et al. · Gut · 2012 · 491 citations · Full text

Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial

Marin J. de Jong, Andrea E. van der Meulen‐de Jong, Mariëlle Romberg‐Camps et al. · The Lancet · 2017 · 347 citations · Full text

Wireless Telemedicine, Remote Patient Monitoring, Telemedicine +8

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial

Cyriel Y. Ponsioen, E. Joline de Groof, Emma J. Eshuis et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 334 citations

Terminal Ileitis, Gastroenterology, Multicentre Trial +4

<i>Helicobacter pylori</i>Modulates the T Helper Cell 1/T Helper Cell 2 Balance through Phase-variable Interaction between Lipopolysaccharide and DC-SIGN

Mathijs P. Bergman, Anneke Engering, Hermelijn H. Smits et al. · The Journal of Experimental Medicine · 2004 · 314 citations · Full text